Global Calcineurin Inhibitor Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Autoimmune Disorders & Organ Transplantation
The global Calcineurin Inhibitor Market is estimated to be valued at US$10.07 billion in 2023 and is expected to exhibit a CAGR of 10.8% over the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Calcineurin inhibitors are immunosuppressive drugs that are commonly used in the treatment of autoimmune disorders and in organ transplantation. These drugs inhibit the enzyme calcineurin, which plays a crucial role in the activation of T-cells in the immune system. By inhibiting calcineurin, these drugs help in preventing the rejection of transplanted organs and in reducing the symptoms associated with autoimmune disorders. Some of the commonly used calcineurin inhibitors include cyclosporine, tacrolimus, and pimecrolimus.
Market Dynamics:
The global calcineurin inhibitor market is primarily driven by two major factors: increasing prevalence of autoimmune disorders and rising number of organ transplantations. The prevalence of autoimmune disorders such as rheumatoid arthritis, psoriasis, and atopic dermatitis has been on the rise globally. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, around 8.5 million people in the United States alone have psoriasis, and around 1.3 million adults have rheumatoid arthritis. The increasing incidence of these disorders has led to a higher demand for calcineurin inhibitors.
In addition, the number of organ transplantations has also been increasing across the globe. According to the Global Observatory on Donation and Transplantation, around 140,000 solid organ transplants were performed globally in 2019. Calcineurin inhibitors are an essential part of the post-transplant immunosuppressive regimen to prevent organ rejection. The growing number of organ transplantations is expected to drive the demand for calcineurin inhibitors.
SWOT Analysis:
Strengths:
1. Efficacy in preventing organ rejection
2. Widely used in the treatment of autoimmune disorders
Weaknesses:
1. Side effects associated with long-term use
2. High cost of treatment
Opportunities:
1. Increasing research and development activities for novel calcineurin inhibitors
2. Growing demand from developing countries with a rising prevalence of autoimmune disorders
Threats:
1. Stringent regulatory requirements for drug approval
2. Availability of alternative immunosuppressive drugs
Key Takeaways:
- The global calcineurin inhibitor market is expected to witness high growth, exhibiting a CAGR of 10.8% over the forecast period, due to increasing prevalence of autoimmune disorders and organ transplantation.
- North America is expected to dominate the market, attributed to the high prevalence of autoimmune disorders and well-established healthcare infrastructure.
- Key players operating in the global Calcineurin Inhibitor Market Growth include Novartis AG, Astellas Pharma Inc., LEO Pharma A/S, Allergan, Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Roche Holding AG, Bristol Myers Squibb Company, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Mylan N.V.
In conclusion, the global calcineurin inhibitor market is projected to experience significant growth in the coming years, driven by the increasing prevalence of autoimmune disorders and the rising number of organ transplantations. However, the market may face challenges such as the high cost of treatment and side effects associated with long-term use. Continued research and development efforts, along with advancements in drug delivery systems, are expected to create lucrative opportunities for market players in the future.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian